Approximation Results for Parameter Estimation in Nonlinear Elastomers

H. Banks,G. Pinter

DOI: https://doi.org/10.1007/978-3-0348-8849-3_1

Abstract:

What problem does this paper attempt to address?

AGEs Increased Migration and Inflammatory Responses of Adventitial Fibroblasts Via RAGE, MAPK and NF-κB Pathways

YaYang Liu,Chun Liang,Xing Liu,Bin Liao,Xiaoming Pan,Yusheng Ren,Min Fan,Mei Li,Zhiqing He,Jianxiang Wu,ZongGui Wu

DOI: https://doi.org/10.1016/j.atherosclerosis.2009.06.007

IF: 5.3

2010-01-01

Atherosclerosis

Abstract:Objective: Advanced glycation end products (AGEs) and vascular adventitial fibroblasts (AFs) are involved in diabetes-related vascular complications. However, the effect of AGEs on AFs remains unclear. The aim of this study was to observe the impact of AGEs on cell migration capacity and associated inflammatory responses of AFs.Methods and results: Isolated vascular AFs of Sprague-Dawley rats were cultured, harvested after 24 h synchronization and challenged with AGE-HSA. AGE-HSA upregulated the expression of receptor for advanced glycation end products (RAGE), significantly increased the migration capacity and inflammatory mediators MCP-1, IL-6, VCAM-1 expressions on AFs. These effects could be significantly attenuated by anti-RAGE neutralizing antibody, p38, ERK1/2 and JNK MAPK inhibitors as well as by candesartan. AGE-HAS also upregulated NF-kappa B transcriptional activity and I-kappa B-alpha phosphorylation, effect that was significantly inhibited by candesartan.Conclusions: AGE-HSA increased the migration capacity and inflammatory responses of rat AFs via RAGE-MAPK-NF-kappa B pathways. Candesartan effectively inhibited these effects which might be a novel vascular protection mechanism of candesartan. (C) 2009 Published by Elsevier Ireland Ltd.
Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Chun Liang,Yusheng Ren,Hongbin Tan,Zhiqing He,Qijun Jiang,Jianxiang Wu,Yi Zhen,Min Fan,Zonggui Wu

DOI: https://doi.org/10.1111/j.1476-5381.2009.00450.x

IF: 7.3

2009-01-01

British Journal of Pharmacology

Abstract:Background and purpose:Advanced glycation end products (AGEs) and endothelial progenitor cells (EPCs) play key roles in pathogenesis of diabetes-related vascular complications. AGEs can induce dysfunction in EPCs. The peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists are widely used in the treatment of type 2 diabetes, and it remains unknown if they could attenuate EPC dysfunction induced by AGEs.Experimental approach:EPCs isolated from healthy adults were cultured with various concentrations of AGEs (0, 50, 100 and 200 mg center dot L-1) with or without rosiglitazone (10 nM), antibody for the receptors for AGE-human serum albumin (anti-receptor for advanced glycation end products (RAGE); 50 mu g center dot mL-1), phosphatidylinositol-3-kinase (PI3K) inhibitor (LY294002, 5 mu M), nitric oxide (NO) synthase inhibitor (L-NG-nitro-arginine methyl ester (L-NAME), 100 mu M) or sodium nitroprusside (SNP, 25 mu M). Proliferation, apoptosis, cell adhesion, migration and NO production in EPCs were assessed, and expressions of endothelial NO synthase (eNOS) and Akt were determined.Key results:Number, proliferation/migration capacities, eNOS and Akt phosphorylation as well as NO synthesized by EPCs were increased by rosiglitazone and reduced by AGEs. AGEs promoted while rosiglitazone reduced EPC apoptosis. The AGE-induced effects were significantly ameliorated by pre-incubation with rosiglitazone, RAGE antibody and SNP. The beneficial effects of rosiglitazone could be blocked by pretreatment with L-NAME and LY294002.Conclusions and implications:The PPAR gamma agonist rosiglitazone increased EPC function and attenuated EPC dysfunction induced by AGEs via upregulating the Akt-eNOS signal pathways of EPCs.
Agonists at PPAR‐γ Suppress Angiotensin II‐induced Production of Plasminogen Activator Inhibitor‐1 and Extracellular Matrix in Rat Cardiac Fibroblasts

G-H Hao,X-L Niu,D-F Gao,J. Wei,N-P Wang

DOI: https://doi.org/10.1038/bjp.2008.21

IF: 7.3

2008-01-01

British Journal of Pharmacology

Abstract:Background and purpose: Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit cardiac fibrosis. However, the underlying mechanisms are poorly understood. We investigated the regulation by PPAR-gamma ligands of angiotensin (Ang) II-induced plasminogen activator inhibitor (PAI)-1, extracellular matrix (ECM) production and cell growth in cardiac fibroblasts.Experimental approach: The effects of PPAR-gamma ligands on Ang II-induced PAI-1, ECM expression and cell growth were assessed in primary-cultured rat cardiac fibroblasts; cardiac PAI-1 and ECM production was examined in Ang II-infused rats.Key results: In growth-arrested cardiac fibroblasts, PPAR-gamma ligands rosiglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)) dose-dependently attenuated Ang II-induced cell proliferation and expression of PAI-1, collagen type-I, collagen type-III and fibronectin. An accompanying increase in PPAR-gamma expression and activation was also observed. These suppressive effects were attenuated by the PPAR-gamma antagonists GW9662 and bisphenol A diglycidyl ether ( BADGE). Moreover, rosiglitazone and 15d-PGJ(2) inhibited in part the expression and phosphorylation of Ang II-induced transforming growth factor ( TGF)-beta 1, Smad2/3 and c-Jun NH(2)-terminal kinase (JNK). Ang II infusion in rats markedly increased left ventricular production of PAI-1, collagen and fibronectin, with a concurrent increase in the ratios of heart weight/body weight and left ventricle weight/body weight. Co-treatment with rosiglitazone significantly decreased these levels and upregulated PPAR-gamma expression.Conclusions and implications: Rosiglitazone and 15d-PGJ2 suppress Ang II-induced production of PAI-1 and ECM probably via interactions between PPAR-gamma and TGF-beta 1/Smad2/3 and JNK signalling pathways. It is suggested that PPAR-gamma and its ligands may have potential applications in preventing cardiac fibrosis.
Effects of combination of pioglitazone and rosuvastatin on rat adventitial fibroblasts oxidization and inflammation induced by Ang Ⅱ

TAO Yang-chen,MIAO Pei-zhi,ZHAO Li-fang,GAO Ping-jin,GU Shui-ming

DOI: https://doi.org/10.13312/j.issn.1671-7783.2013.02.006

2013-01-01

Abstract:Objective: To investigate the effect and possible mechanism of peroxisome proliferators activated receptor(PPAR) γ agonists pioglitazone and rosuvastatin on rat aortas adventitial fibroblasts(AFs) oxidization and inflammation.Methods: Adventitial fibroblast(AF) were prepared from rat aortas using explant technique and cultured for passages.The fourth passage were used and into five groups: the control group,AngⅡ group,pioglitazone group,rosuvastatin group,pioglitazone and rosuvastatin group.The effects of AngⅡ on the NADPH oxidase subunits with or without rosuvastatin and pioglitazone were investigated by Western-blot.The levels of transcription factors NF-κB and activator protein-1(AP-1) were measured by electrophoretic mobility shift assay.PPARγ mRNA level was detected by reverse transcription-polymerase chain reaction(RT-PCR).Results: ① AngⅡ induced the expressions of NADPH oxidase subunits p22phox and p67phox(P<0.01).PPARγ agonists pioglitazone alone or the combination with rosuvastatin inhibited these effects by AngⅡ(P<0.05).② AngⅡ stimulated the activations of transcription factors NF-κB and AP-1,pioglitazone reduced NF-κB,rosuvastatin reduced AP-1,and the combination of pioglitazone and rosuvastatin reduced both NF-κB and AP-1 at the same time.③ Pioglitazone and rosuvastatin alone or the combination induced the expression of PPARγ mRNA(P<0.01).The combination had the further effect(P<0.05).Conclusion: The combination of pioglitazone and rosuvastatin may further inhibit the oxidant and inflammatory effects on rat AFs induced by AngⅡ,which may be mediated with upregulating PPARγ mRNA level by statins.
Alendronate prevents angiotensin II-induced collagen I production through geranylgeranylation-dependent RhoA/Rho kinase activation in cardiac fibroblasts.

Yang Ye,Xue Lv,Mei-hui Wang,Jun Zhu,Shi-quan Chen,Chen-yang Jiang,Guo-sheng Fu

DOI: https://doi.org/10.1016/j.jphs.2015.10.006

IF: 3.578

2015-01-01

Journal of Pharmacological Sciences

Abstract:Collagen I is the main component of extracellular matrix in cardiac fibrosis. Our previous studies have reported inhibition of farnesylpyrophosphate synthase prevents angiotensin II-induced cardiac fibrosis, while the exact molecular mechanism was still unclear. This paper was designed to investigate the effect of alendronate, a farnesylpyrophosphate synthase inhibitor, on regulating angiotensin II-induced collagen I expression in cultured cardiac fibroblasts and to explore the underlying mechanism. By measuring the mRNA and protein levels of collagen I, we found that alendronate prevented angiotensin II-induced collagen I production in a dose-dependent manner. The inhibitory effect on collagen I expression was reversed by geranylgeraniol, and mimicked by inhibitors of RhoA/Rho kinase pathway including C3 exoenzyme and GGTI-286. Thus we suggested geranylgeranylation-dependent RhoA/Rho kinase activation was involved in alendronate-mediated anti-collagen I synthetic effect. Furthermore, we accessed the activation status of RhoA in alendronate-, geranylgeraniol- and GGTI-286-treated cardiac fibroblasts and gave an indirect evidence for RhoA activation via geranylgeranylation. Then we came to the conclusion that in cardiac fibroblasts, alendronate could protect against angiotensin II-induced collagen I synthesis through inhibition of geranylgeranylation and inactivation of RhoA/Rho kinase signaling. Targeting geranylgeranylation and RhoA/Rho kinase signaling will hopefully serve as therapeutic strategies to reduce fibrosis in heart remodeling.
Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

TAN Hongbin,JIANG Qijun,WU Jianxiang,LIANG Chun,LIU Xing,REN Yusheng,WU Zonggui

2009-01-01

Abstract:Objective To investigate whether peroxisome proliferator-activated receptor-gamma(PPARγ)agonists rosiglitazone can ameliorate the dysfunction of endothelial progenitor cells(EPCs)induced by advanced glycation end products(AGEs).Methods EPCs isolated from healthy adults were cultured with various concentrations of advanced glycation end product-human serum albumin(AGE-HSA)(0,50,100 and 200 mg/L)for 24 h in the absence or presence of rosiglitazone(10 nmol/L),anti-RAGE antibody(50 mg/L).We also included a blank control group.The proliferation,apoptosis,cell adhesion,migration,NO production and vascular cell adhesion molecule(VCAM)-1 secretion by EPCs were assessed.Results AGE-HSA at 200 mg/L significantly impaired the proliferation(reduced by [37.7±6.3]% compared with control,P<0.05),adherent([35.6±1.5]/HPF vs.[20.2±1.3]/HPF,P<0.05),and migration([28.6±2.8]/HPF vs.[15.0±2.1]/HPF,P<0.05)of EPCs,and aggravated the apoptosis([4.6±0.8]% vs.[15.2±1.0]%,P<0.05)of EPCs.Rosiglitazone significantly reversed the impairment effect of AGE-HSA on the proliferation(increased to [89.3±5.9]%,P<0.05),adherent(increased to [31.2±2.6]/HPF,P<0.05)and migration(increased to [21.6±3.1]/HPF,P<0.05)of EPCs,and ameliorated the apoptosis(reduced to [6.1±0.9]%,P<0.05)of EPCs.Rosiglitazone also increased the production of NO([16.2±1.0]μmol/L vs.[10.2±0.5] μmol/L,P<0.05)and reduced the secretion of VCAM-1([5.2±0.04] μg/L vs.[6.2±0.1] μg/L,P<0.05)of EPCs.Conclusion PPARγ agonist rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products.
Rosiglitazone Inhibits Angiotensin Ii-Induced Ctgf Expression in Vascular Smooth Muscle Cells - Role of Ppar-Gamma in Vascular Fibrosis

Deng-Feng Gao,Xiao-Lin Niu,Guang-Hua Hao,Ning Peng,Jin Wei,Ning,Nan-Ping Wang

DOI: https://doi.org/10.1016/j.bcp.2006.09.019

IF: 6.1

2006-01-01

Biochemical Pharmacology

Abstract:Angiotensin (Ang) II plays a pivotal role in vascular fibrosis, which leads to serious complications in hypertension and diabetes. Connective tissue growth factor (CTGF) is a potent profibrotic factor implicated in the Ang II-induced pathologic fibrosis process. PPAR-γ activators thiazolidinediones have been recently reported to have beneficial vascular effects. However, their effects and related molecular mechanisms on extracellular matrix (ECM) turnover in vascular smooth muscle cells (VSMCs) are unknown. The present study evaluated the regulation of Ang II-induced CTGF, ECM production and cell growth by rosiglitazone in VSMCs. In aorta of Ang II-infused rats, CTGF expression was markedly increased, and type III collagen and fibronectin overexpression was observed. Cotreatment with rosiglitazone diminished these changes, whereas increased nuclear PPAR-γ expression in VSMCs. In growth-arrested VSMCs, rosiglitazone attenuated the proliferation and apoptosis, increased PPAR-γ production and activation, and reduced CTGF and ECM production in response to Ang II in a dose-dependent fashion. These inhibitory effects were attenuated by the pretreatment of cells with PPAR-γ antagonist GW9662 or bisphenol A diglycidyl ether (BADGE). Furthermore, rosiglitazone inhibited Ang II-induced Smad2 production and phosphorylation but had no effect on transforming growth factor-β1 (TGF-β1) expression. These results suggest that in Ang II-stimulated VSMCs, rosiglitazone caused an antiproliferative, antiapototic effect and reduces ECM production through mechanisms that include reducing CTGF expression, and a crosstalk between PPAR-γ and Smad may be involved in the inhibitory effects of rosiglitazone. This novel finding suggests a role of PPAR-γ activators in preventing Ang II-induced vascular fibrosis.
A12570 Angiotensin II Type 1 Receptor Mediates the Expression of Collagen Type 1 in Homocysteine Stimulated Rat Adventitial Fibroblasts by ERK1/2-STAT3 Pathway

Liu Xiaoyun,Ningling Sun

DOI: https://doi.org/10.1097/01.hjh.0000548273.63278.e3

IF: 4.9

2018-01-01

Journal of Hypertension

Abstract:Objectives: We aimed to explore Homocysteine (Hcy) on the expression of collagen type 1 and angiotensin II type 1 receptor (AT1 R) in rat aortic adventitial fibroblasts (AFs), and to investigate the mechanism and signaling pathway of Hcy aggravated vascular remodeling Methods: The Paste tissue pieces method was used to cultivate original generation fibroblasts of adventitia isolated from thoracic aorta of male Sprague-Dawley rats. AFs were divided into four groups: Control group: cultured cells without Hcy; Hcy group: AFs stimulated by Hcy at different concentration (50, 100, 200 μmol/L) and different time (12, 24, 48 hours); Hcy+U0126 group: AFs were pretreated with U0126 (ERK1/2 blocker, 10 μmol/L) for 30 min, then stimulated by Hcy (100 μmol/L) for 24 h; DMSO group: AFs stimulated by DMSO (10 μmol/L) for 24 h. The expression of collagen type 1, AT1 R, p-ERK1/2, p-STAT3 and t-ERK1/2 were measured by western blot Results: With the increase of concentration and treated time of Hcy, the expression of collagen type 1 and AT1 R increased, and the maximal effect appears at concentration of 100 μmol/L Hcy and at 48 h. This dose- and time-response fashion was also observed in the expression of p-STAT3 and p-ERK1/2. U0126 (10 μmol/L) could significantly block the pathway of ERK1/2- STAT3 and then inhibit the expression of collagen type 1 and AT1 R, compared with 100 μmol/L Hcy group Conclusion: Hcy could increase the expression of collagen type 1 and AT1 R in AFs in rats, which is partly through the activation of ERK1/2- STAT3 signal pathway, contributing to the development of vascular remodeling. This effect could significantly inhibit by ERK1/2 blocker-U0126
Effects of rosiglitazone on rat aortic adventitial fibroblasts migration induced by angiotensinⅡ

MIAO Peizhi,JIN Xian,WANG Haiya

2008-01-01

Abstract:Aim: To explore the effect of PPARγ activators,rosiglitazone on the migration induced by angiotensinⅡ(AngⅡ) in cultured aortic adventitial fibroblasts(AFs).Methods:AFs were prepared from rat aortas using explant technique and cultured for passages.The fifth passage cells were used.The AFs were allocated into 5 groups: control group,AngⅡgroup,AngⅡ+0.1 μmol/L ROSI group,AngⅡ+1.0 μmol/L ROSI group,and AngⅡ+10 μmol/L ROSI group.Cell migration was determined by Transwell Chamber.Additionally,the AFs were allocated into 4 groups: control group,AngⅡgroup,AngⅡ+10 μmol/L ROSI group,and AngⅡ+10 μmol/L ROSI+GW9662 group.The expression and activity of MMP-2 were determined by Western blotting and zymography,respectively.Results: AngⅡ significantly induced the migration of AFs,which was inhibited by pretreatment with rosiglitazone in a dose-dependent manner.Rosiglitazone could attenuate the expression of MMP-2 protein and the activity of MMP-2.Conclusion: Rosiglitazone can obviously attenuate the expression and activity of MMP-2 induced by AngⅡ,which may be realized by inhibiting the migration of AFs.
Peroxisome Proliferator-Activated Receptor α Attenuates Hypertensive Vascular Remodeling by Protecting Vascular Smooth Muscle Cells from Angiotensin II-Induced ROS Production

Ye Liu,Yan Duan,Nan Zhao,Xinxin Zhu,Xiaoting Yu,Shiyu Jiao,Yanting Song,Li Shi,Yutao Ma,Xia Wang,Baoqi Yu,Aijuan Qu

DOI: https://doi.org/10.3390/antiox11122378

IF: 7.675

2022-12-01

Antioxidants

Abstract:Vascular remodeling is the fundamental basis for hypertensive disease, in which vascular smooth muscle cell (VSMC) dysfunction plays an essential role. Previous studies suggest that the activation of peroxisome proliferator-activated receptor α (PPARα) by fibrate drugs has cardiovascular benefits independent of the lipid-lowering effects. However, the underlying mechanism remains incompletely understood. This study explored the role of PPARα in angiotensin II (Ang II)-induced vascular remodeling and hypertension using VSMC-specific Ppara-deficient mice. The PPARα expression was markedly downregulated in the VSMCs upon an Ang II treatment. A PPARα deficiency in the VSMC significantly aggravated the Ang II-induced hypertension and vascular stiffness, with little influence on the cardiac function. The morphological analyses demonstrated that VSMC-specific Ppara-deficient mice exhibited an aggravated vascular remodeling and oxidative stress. In vitro, a PPARα deficiency dramatically increased the production of mitochondrial reactive oxidative species (ROS) in Ang II-treated primary VSMCs. Finally, the PPARα activation by Wy14643 improved the Ang II-induced ROS production and vascular remodeling in a VSMC PPARα-dependent manner. Taken together, these data suggest that PPARα plays a critical protective role in Ang II-induced hypertension via attenuating ROS production in VSMCs, thus providing a potential therapeutic target for hypertensive diseases.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
Abstract 1357: PGC-1 Α As a Novel Regulator for Angiotensin II-induced Reactive Oxygen Species Production and Hypertrophy in Vascular Smooth Muscle Cells

Shiqin Xiong,Mushtaq Ahmad,Nikolay A. Patrushev,Lula Hilenski,San Martin Almeyda Alejandra,Masuko Ushio-Fukai,Alexander R. Wayne

DOI: https://doi.org/10.1161/circ.118.suppl_18.s_312-c

IF: 37.8

2008-01-01

Circulation

Abstract:Angiotensin II (Ang II) increases H 2 O 2 production and vascular smooth muscle cell (VSMCs) hypertrophy, in part through redox-sensitive PI3K/Akt, which is inhibited by catalase overexpression. The relevant molecular mechanism remains unclear. Peroxisome proliferator-activated receptor gamma coactivator-1 α (PGC-1 α ) is reported to protect from oxidative stress by regulating expression of antioxidant enzymes such as catalase. We thus hypothesized that PGC-1 α may be important mediator for Ang II-induced H2O2 production and vascular hypertrophy. Here we show that Ang II stimulation increases serine phosphorylation of PGC-1 α (2.2 folds) with a peak at 15 min, which is inhibited by LY294002, a specific PI3 kinase inhibitor (98% decrease), and by Akt inhibitor-2/Triciribine (95% decrease). Ang II promotes PGC-1 α phosphorylation mainly at Ser 570 in an Akt-dependent manner. Ang II significantly suppresses Gal4-fused PGC-1 α transcriptional activity in a dose dependent manner, which is partially reversed by PI3K/Akt inhibition. Chromatin immunoprecipitation (ChIP) assay shows that PGC-1 α associates with the catalase promoter and this association is blocked by Ang II in a PI3K/Akt-dependent manner. Consistent with these results, Ang II stimulation time-dependently decreases endogenous catalase expression at both messenger RNA and protein levels. Ang II-induced downregulation of catalase at protein level at 24 hrs is prevented by Akt inhibitor (86%) and by overexpression of PGC-1 α S570A, an Akt phosphorylation site mutant, (75%). Moreover, overexpression of PGC-1 α S570A significantly inhibits Ang II-induced increase in H2O2 production (>80%) and leucine incorporation (>90%) as measured at 12 and 24 hrs, respectively. In summary, Akt-dependent serine phosphorylation of PGC-1 α by Ang II plays an important role for Ang II-induced downregulation of catalase, thereby increasing H2O2 production, which may contribute to ROS-dependent VSMC hypertrophy. These findings provide insight into a novel mechanisms by which Ang II promotes long-term H2O2 production to increase oxidative stress via targeting PGC-1alpha, and mediates metabolic abnormalities.
Recent Technical Trends of Optical Memory

K. Goto

1999-08-25

Abstract:SUMMARY Recent technologies for increasing memory density in random access memory optical disks including magnetic super resolution method, super resolution method in phase change disk, blue laser diode, near field optics, and photo chromic memory are reviewed.
Angiotensin II regulates collagen metabolism through modulating tissue inhibitor of metalloproteinase-1 in diabetic skin tissues

Meng Ren,Shaoyun Hao,Chuan Yang,Ping Zhu,Lihong Chen,Diaozhu Lin,Na Li,Li Yan

DOI: https://doi.org/10.1177/1479164113485461

2013-06-23

Diabetes and Vascular Disease Research

Abstract:We investigated the effect of angiotensin II (Ang II) on matrix metalloproteinase-1 (MMP-1)/tissue inhibitor of metalloproteinase-1 (TIMP-1) balance in regulating collagen metabolism of diabetic skin. Skin tissues from diabetic model were collected, and the primary cultured fibroblasts were treated with Ang II receptor inhibitors before Ang II treatment. The collagen type I (Coll I) and collagen type III (Coll III) were measured by histochemistry. The expressions of transforming growth factor-β (TGF-β), MMP-1, TIMP-1 and propeptides of types I and III procollagens in skin tissues and fibroblasts were quantified using polymerase chain reaction (PCR), Western blot or enzyme-linked immunosorbent assay (ELISA). Collagen dysfunction was documented by changed collagen I/III ratio in streptozotocin (STZ)-injected mice compared with controls. This was accompanied by increased expression of TGF-β, TIMP-1 and propeptides of types I and III procollagens in diabetic skin tissues. In primary cultured fibroblasts, Ang II prompted collagen synthesis accompanied by increases in the expressions of TGF-β, TIMP-1 and types I and III procollagens, and these increases were inhibited by losartan, an Ang II type 1 (AT1) receptor blocker, but not affected by PD123319, an Ang II type 2 (AT2) receptor antagonist. These findings present evidence that Ang-II-mediated changes in the productions of MMP-1 and TIMP-1 occur via AT1 receptors and a TGF-β-dependent mechanism.

endocrinology & metabolism,peripheral vascular disease
17Β-Estradiol Inhibits Angiotensin II-induced Collagen Synthesis of Cultured Rat Cardiac Fibroblasts Via Modulating Angiotensin II Receptors

Li Zhou,Ying Shao,Yu Huang,Tai Yao,Li-Min Lu

DOI: https://doi.org/10.1016/j.ejphar.2007.03.047

IF: 5.195

2007-01-01

European Journal of Pharmacology

Abstract:Circulating endogenous estrogen is considered to be cardiovascular protective, but the underlying mechanisms remain obscure. The cardiac fibroblasts, the most abundant cell type present in the heart, are responsible for the deposition of extracellular matrix. Angiotensin II has been known to stimulate cardiac collagen gene expression. The present study was designed to investigate the effect of 17beta-estradiol on the angiotensin II-induced proliferation and collagen synthesis in cultured cardiac fibroblasts by using real-time polymerase chain reaction (PCR), Western blot and 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl-tetrazolium bromide proliferation assay. Angiotensin II increased the cell proliferation and synthesis of collagen types I and III. Angiotensin II up-regulated the gene expression of the angiotensin AT(1) receptor and down-regulated the gene expression of the angiotensin AT(2) receptor in cardiac fibroblasts. The effects of angiotensin II was abolished by the angiotensin AT(1) receptor antagonist, losartan, but not by the angiotensin AT(2) receptor antagonist, PD 123319. 17beta-estradiol prevented increases in proliferation and attenuated the collagen synthesis in response to angiotensin II. The increased AT(1) receptor mRNA levels and decreased AT(2) receptor mRNA levels were partially reversed by 17beta-estradiol treatment. In conclusion, the down-regulation of angiotensin AT(1) receptor expression and function is likely to be an important mechanism accounting for the inhibitory effect of 17beta-estradiol on angiotensin II-stimulated proliferation and collagen synthesis in cardiac fibroblasts. This effect may confer at least in part the cardiac protective action of 17beta-estradiol under pathological conditions with increased activity of the rennin-angiotensin system.
Modified vastus lateralis flap in treating a difficult hip infection.

Kuo-Chin Huang,Kuo-Ti Peng,Yen-Yao Li,Yao-Hung Hubert Tsai,Tsung-Jen Huang,R. Hsu

DOI: https://doi.org/10.1097/01.TA.0000177677.81638.69

2005-09-01

Abstract:BACKGROUND Difficult-to-treat hip infections are typically a reconstructive challenge to orthopedic surgeons. Treatment regimens must be tailored to each patient on the basis of an overall evaluation of systemic host factors and local wound factors. To treat a medically ill patient with compromised local wounds in the hip area, a modified vastus lateralis flap transposition was developed. This flap transposition is of a simple design and effective as both a soft-tissue coverage and a dead space filler. METHODS From January 2002 to June 2003, 10 patients (5 male patients and 5 female patients) suffering difficult hip infections were referred to Chang Gung Memorial Hospital at Chia-Yi for further treatment. Before visiting the clinic, each patient had undergone repeated failed operations, including debridement, introduction of antibiotic-loaded cement spacers, and fasciocutaneous flap transposition. After being diagnosed with difficult hip infections, these patients were treated with the modified vastus lateralis flap transposition immediately after radical debridement. The average follow-up period was 17.4 months (range, 9-27 months). RESULTS The hip infections in all 10 patients were controlled and the wounds healed uneventfully. The need for another soft-tissue procedure was not indicated. The C-reactive protein returned to a near-normal and stable level within 1 month. The only complication occurred when case 1 developed a contralateral iliopsoas abscess and secondary septic hip 9 months after the procedure. There was no morbidity or mortality related to the technique. CONCLUSION For medically ill patients with compromised local wounds, the modified vastus lateralis muscle flap transposition after radical debridement is a simple and effective way of resolving refractory and limb-threatening hip infections.
Puerarin Decreases Collagen Secretion in AngII-Induced Atrial Fibroblasts Through Inhibiting Autophagy Via the JNK-Akt-mTOR Signaling Pathway.

Xudong Xu,Ruhong Jiang,Mengmeng Chen,Mengmeng Dong,Qiang Liu,Hui Cheng,Kuangshi Zhou,Laite Chen,Miaomiao Li,Chenyang Jiang

DOI: https://doi.org/10.1097/FJC.0000000000000672

IF: 3.271

2019-01-01

Journal of Cardiovascular Pharmacology

Abstract:Puerarin is used to treat cardiovascular diseases due to its anti-inflammatory and antifibrotic effects. However, its mechanism of action in atrial fibroblasts is unknown. In this study, we investigated the autophagy pathway and molecular changes in angiotensin II (AngII)-stimulated atrial fibroblasts in response to puerarin treatment. Atrial fibroblasts were cultured and then subjected to stimulation with AngII and puerarin or other chemical drugs (3-MA, CQ, and SP600125). Quantitative real-time polymerase chain reaction and Western blot experiments were used to quantify the expression levels of mRNA and protein. mCherry-GFPLC3 adenovirus was applied to reflect the autophagic flux. The results showed aggravating levels of autophagy and collagen deposit in the presence of AngII. Puerarin inhibited autophagy and decreased collagen secretion in a dose-dependent manner in atrial fibroblasts. Furthermore, phosphorylation of JNK was down-regulated in response to puerarin, whereas phosphorylation of Akt and mammalian target of rapamycin (mTOR) was upregulated. Interestingly, reduced autophagy and collagen secretion were observed when the JNK signaling pathway was blocked using SP600125. We also observed upregulation of Akt and mTOR phosphorylation in the presence of SP600125. These results suggest that puerarin exerts its antifibrotic effect in atrial fibroblasts partly through the inhibition of autophagy. Furthermore, the mechanism of action of puerarin in fibroblast autophagy seems to be mediated partly through JNK-Akt-mTOR signaling.
GW24-e3020 Involvement of vascular peroxidase 1 in angiotensin II-induced H9c2 cells hypertrophy

Yang Wei,Ruizheng Shi

DOI: https://doi.org/10.1136/heartjnl-2013-304613.196

IF: 5.7

2013-08-01

Heart

Abstract:Oxidative stress induces hypertrophic gene expression and collagen deposition that mediates cardiac hypertrophy and myocardial fibrosis. Vascular peroxidase 1 (VPO1) is a new heme-containing peroxidase, which can utilise hydrogen peroxide (H2O2) generated from co-expressed NADPH oxidase (NOX) to produce hypochlorous acid (HOCl) and catalyse peroxidative reactions. Our previous studies had found that NOX/VPO1 pathway-mediated oxidative stress plays an important role in myocardial ischaemia-reperfusion injury. This study was aim to investigate whether VPO1 mediate angiontensin II induced cardiac hypertrophy in H9c2 cells and to explore the underlying mechanism. Cultured H9c2 cells were treated with angiotensin II, cell hypertrophy were measured by cellular surface size, brain natriuretic peptide (BNP) and atrial natriuretic factor (ANF) gene expression. The effects of NADPH oxidase inhibitor, diphenyleneiodonium (DPI), hydrogen peroxide scavenger, catalase, VPO1 inhibitor 4-aminobenzoic acid hydrazide (ABAH) on cell hypertrophy, VPO1 expression, H2O2 and HOCl production were measured. And the effect of ABAH on the mitogen-activated protein kinase pathway including p-38, p-JNK and p-ERK were determined. Angiotensin II treatment significantly increased the cellular size and the gene expression of BNP, ANF while up-regulated the VPO1 expression and HOCl production. These effects were inhibited by pretreatment with DPI, catalase and ABAH. Moreover, pretreatment with ABAH abolished the angiotensin II-induced up-regulation of p-ERK activity, not p-38, p-JNK expression. These results indicated that VPO1 play a role in anngitotensin II induced cell hyperthrophy via NOX-H2O2-VPO1-HOCl-ERK1/2 pathway.

cardiac & cardiovascular systems
[Hesperetin attenuates angiotensin II-induced collagen expression in cardiac fibroblasts in vitro].

Yuan Liu,Qizhu Tang,Lina Li,Wei Liu,Rong Jiao,Wei Deng

DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2014.36.013

2014-01-01

Abstract:OBJECTIVE:To explore the effect of hesperetin (HES) on collagen expression in cardiac fibroblasts in vitro induced by angiotensin II (AngII). METHODS:Cell growth was determined by trypan blue staining, reactive oxygen species (ROS) generation by microplate reader, the expressions of collagen I,III and matrix metalloproteinase 1 (MMP-1) by real-time polymerase chain reaction (PCR) and cell proliferation by cell counting kit-8. RESULTS:HES and AngII+HES had no effect on cellular activity. AngII significantly increased ROS generation (1.70 ± 0.12 vs 1, P < 0.01), gene expression of collagen I,III both increased (1.31 ± 0.08 vs 1, 1.40 ± 0.09 vs 1, both P < 0.01) while MMP-1 decreased (0.68 ± 0.03 vs 1, P < 0.01). Ang II also induced the proliferation of fibroblasts (1.91 ± 0.18 vs 1, P < 0.01). While HES (25, 50, 100 µmol/L) or NAC (1 mmol/L) reversed these effects during co-treating with AngII, ROS decreased versus the Ang II group(1.37 ± 0.05, 1.16 ± 0.08, 1.07 ± 0.07, 1.12 ± 0.07 vs 1.70 ± 0.12, all P < 0.01) , gene expression of collagenI,III also decreased (1.22 ± 0.08 and 1.27 ± 0.07, 1.14 ± 0.07 and 1.00 ± 0.06, 1.02 ± 0.06 and 0.99 ± 0.05, 1.08 ± 0.07 and 1.09 ± 0.06 vs 1.31 ± 0.08 and 1.40 ± 0.09, all P < 0.01), MMP-1 increased (0.76 ± 0.05, 0.88 ± 0.07, 1.01 ± 0.08, 0.96 ± 0.07 vs 0.68 ± 0.03, P < 0.01) versus the Ang II group. Cell proliferation was also inhibited (1.42 ± 0.07, 1.38 ± 0.03, 1.07 ± 0.15, 1.16 ± 0.11 vs 1.91 ± 0.18, all P < 0.01). NAC had the same effect with HES. CONCLUSION:HES inhibits the synthesis of collagen and the Ang II-induced proliferation of fibroblast through suppressing the ROS generation.
Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin.

C Chatziantoniou,J J Boffa,R Ardaillou,J C Dussaule

DOI: https://doi.org/10.1172/jci2132

IF: 19.456

1998-06-15

Journal of Clinical Investigation

Abstract:Hypertension is often associated with the development of nephroangio- and glomerulo-sclerosis. This pathophysiological process is due to increased extracellular matrix protein, particularly type I collagen, accumulation. This study investigated whether nitric oxide (NO) synthesis is involved in the mechanism(s) regulating activation of the collagen I gene in afferent arterioles and glomeruli. Experiments were performed on transgenic mice harboring the luciferase gene under the control of the collagen I-alpha2 chain promoter [procolalpha2(I)]. Measurements of luciferase activity provide highly sensitive estimates of collagen I gene activation. NO synthesis was inhibited by NG-nitro-L-arginine methyl ester (L-NAME) (20 mg/kg per day) for a period of up to 14 wk. Systolic blood pressure was increased after 6 wk of treatment (117+/-2 versus 129+/-2 mmHg, P < 0.01) and reached a plateau after 10 wk (around 160 mmHg). Luciferase activity was increased in freshly isolated afferent arterioles and glomeruli as early as week 4 of L-NAME treatment (150 and 200% of baseline, P < 0.01, respectively). The activation of procolalpha2(I) became more pronounced with time, and at 14 wk increased four- and tenfold compared with controls in afferent arterioles and glomeruli, respectively (P < 0.001). In contrast, luciferase activity remained unchanged in aorta and heart up to 8 wk and was increased thereafter. Increased histochemical staining for extracellular matrix deposition, and particularly of collagen I, was detected in afferent arterioles and glomeruli after 10 wk of L-NAME treatment. This fibrogenic process was accompanied by an increased urinary excretion rate of endothelin. In separate experiments, the stimulatory effect of L-NAME on collagen I gene activation was abolished when animals were treated with bosentan, an endothelin receptor antagonist. Similarly, bosentan reduced the increased extracellular matrix deposition in afferent arterioles and glomeruli during NO inhibition. Interestingly, bosentan had no effect on the L-NAME- induced increase of systolic pressure. These data indicate that NO inhibition induces an early activation of the collagen I gene in afferent arterioles and glomeruli. This activation in the kidney precedes the increase in blood pressure and the procolalpha2(I) activation in heart and aorta, suggesting a specific renal effect of NO blockade on collagen I gene expression that is independent of increased blood pressure and, at least partly, mediated through stimulation of the endothelin receptor. Use of procolalpha2(I) transgenic mice provides a novel and efficient model to study the pathophysiological mechanism(s) regulating renal fibrosis.

medicine, research & experimental
Peroxisome proliferator activated receptor gamma ligand suppresses hepatic fibrosis in rats

Yan-tong GUO,Jing-ming ZHAO,Lei SONG,Mai ZHOU,Gang-jun JIAO,Ji-run PENG,Tao LI,Xi-sheng LENG

DOI: https://doi.org/10.3760/j.issn:1007-631X.2008.10.016

2008-01-01

Abstract:Objective To study the effect of peroxisome proliferator-activated receptor garama (PPARγ) ligand on hepatic fibrosis in rats. Methods Forty Wistar rats were randomly divided into two groups: the control group(20 rats) ,in which liver cirrhosis was induced by adding 0. 3‰ thioacetamide in the fodder for 6 months, and rosiglitazone group(20 rats) in which 200 ppm of rosiglitazone in combination with 0. 3‰ thioacetamide was added in the fodder. Liver tissue's mRNA expression of PPARγ, TGF-β1 ,type Ⅰ pro-collagen and α-smooth muscle actin(α-SMA) was detected by RT-PCR. The protein expression of PPARγ, TGF-β1 ,type Ⅰ collagen and α-SMA was detected by Western blot. The expression of collagenof liver histological section was evaluated by Van Gieson (VG) staining. Results The expression ofPPARγ at mRNA level significantly increased in rosiglitazone group compared with those in the control group ( t = 6. 93, P < 0. 01 ), while the expression of TGF-β1 ( t = 3. 89, P < 0. 01 ) and type Ⅰ pro-collagen ( t =5.67,P <0. 01 ) were lower than that in the control group. The protein expression of PPARγ, TGF-β1 and type Ⅰ collagen was in similar tendence with that of mRNA expression. The expression of α-SMA decreased significantly in rosiglitazone group compared with that in the control group (t = 3. 12,P < 0.01 ). The collagen stainings of liver histological section in rosiglitazone group was lower than those in the control group (t = 3.47, P < 0. 01 ). Conclusion PPARγ ligand inhibits the production of collagen in fibrofic livers in rats and prevents hepatic fibrosis in vivo.

Approximation Results for Parameter Estimation in Nonlinear Elastomers

AGEs Increased Migration and Inflammatory Responses of Adventitial Fibroblasts Via RAGE, MAPK and NF-κB Pathways

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Agonists at PPAR‐γ Suppress Angiotensin II‐induced Production of Plasminogen Activator Inhibitor‐1 and Extracellular Matrix in Rat Cardiac Fibroblasts

Effects of combination of pioglitazone and rosuvastatin on rat adventitial fibroblasts oxidization and inflammation induced by Ang Ⅱ

Alendronate prevents angiotensin II-induced collagen I production through geranylgeranylation-dependent RhoA/Rho kinase activation in cardiac fibroblasts.

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Rosiglitazone Inhibits Angiotensin Ii-Induced Ctgf Expression in Vascular Smooth Muscle Cells - Role of Ppar-Gamma in Vascular Fibrosis

A12570 Angiotensin II Type 1 Receptor Mediates the Expression of Collagen Type 1 in Homocysteine Stimulated Rat Adventitial Fibroblasts by ERK1/2-STAT3 Pathway

Effects of rosiglitazone on rat aortic adventitial fibroblasts migration induced by angiotensinⅡ

Peroxisome Proliferator-Activated Receptor α Attenuates Hypertensive Vascular Remodeling by Protecting Vascular Smooth Muscle Cells from Angiotensin II-Induced ROS Production

Abstract 1357: PGC-1 Α As a Novel Regulator for Angiotensin II-induced Reactive Oxygen Species Production and Hypertrophy in Vascular Smooth Muscle Cells

Recent Technical Trends of Optical Memory

Angiotensin II regulates collagen metabolism through modulating tissue inhibitor of metalloproteinase-1 in diabetic skin tissues

17Β-Estradiol Inhibits Angiotensin II-induced Collagen Synthesis of Cultured Rat Cardiac Fibroblasts Via Modulating Angiotensin II Receptors

Modified vastus lateralis flap in treating a difficult hip infection.

Puerarin Decreases Collagen Secretion in AngII-Induced Atrial Fibroblasts Through Inhibiting Autophagy Via the JNK-Akt-mTOR Signaling Pathway.

GW24-e3020 Involvement of vascular peroxidase 1 in angiotensin II-induced H9c2 cells hypertrophy

[Hesperetin attenuates angiotensin II-induced collagen expression in cardiac fibroblasts in vitro].

Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin.

Peroxisome proliferator activated receptor gamma ligand suppresses hepatic fibrosis in rats